Patents by Inventor Gregory D. Cuny

Gregory D. Cuny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240173311
    Abstract: The invention features compounds and a method of treating an injury or a disease e.g., stroke, congenital hypogonadotropic hypogonadism, and viral infection, using the compounds. Also featured is a pharmaceutical composition containing one or more of the compounds, and a method of increasing spermatogenesis using the compounds.
    Type: Application
    Filed: February 11, 2022
    Publication date: May 30, 2024
    Inventors: Seth P. FINKLESTEIN, Gregory D. CUNY, Renato SKERLJ, Soumya RAY, Stephen Douglas BARRETT, Kirk Lang OLSON
  • Publication number: 20240174631
    Abstract: The invention features compounds which modulate FGF activity, e.g., by enhancing the binding between FGF-2 and its receptors, e.g., FGF-R1. Also featured is a pharmaceutical composition containing one or more of the compounds, a method of treating an injury or a disease e.g., stroke, congenital hypogonadotropic hypogonadism, and viral infection, and a method of increasing spermatogenesis using the pharmaceutical composition.
    Type: Application
    Filed: February 11, 2022
    Publication date: May 30, 2024
    Inventors: Seth P. FINKLESTEIN, Gregory D. CUNY, Renato SKERLJ, Soumya RAY, Stephen Douglas BARRETT, Kirk Lang OLSON, Fred Lawrence CISKE, Paige Elizabeth HEIPLE, Melissa Christine HOLT, James Bernard KRAMER
  • Publication number: 20230219898
    Abstract: Disclosed herein are small molecules that inhibit apoptosis and promote autophagy through the TRADD pathway, and their use for treatment of neurodegenerative diseases. Methods of preparing these small molecules and medicinal efficacy are described.
    Type: Application
    Filed: June 16, 2021
    Publication date: July 13, 2023
    Inventors: Junying Yuan, Heng Zhao, Daichao Xu, Mingzhi Jin, Hong Zhu, Gregory D. Cuny
  • Publication number: 20210363154
    Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder hi a subject. For example, the disorder is a neurodegenerative disease.
    Type: Application
    Filed: March 29, 2021
    Publication date: November 25, 2021
    Inventors: Gregory D. CUNY, Marcie A. GLICKSMAN, Steven L. MATHIEU, Yukari Y. PERRELLA, Vincent DARMENCY, Hrvoje LUSIC, Kevin J. HODGETTS
  • Patent number: 11160808
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: November 2, 2021
    Assignees: Massachusetts Eye & Ear Infirmary, Brigham & Women's Hospital, Inc.
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • Patent number: 10961254
    Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder in a subject. For example, the disorder is a neurodegenerative disease.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: March 30, 2021
    Assignees: Yuma Therapeutics, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Gregory D. Cuny, Marcie A. Glicksman, Kevin J. Hodgetts, Steven L. Mathieu, Yukari Y. Perrella, Vincent Darmency, Hrvoje Lusic
  • Publication number: 20200179394
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Application
    Filed: July 22, 2019
    Publication date: June 11, 2020
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • Patent number: 10653676
    Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: May 19, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Alan D. D'Andrea, Gregory D. Cuny, Ross L. Stein, Marcie Glicksman, April Case, Jun Xian, David Wilson, Min Huang
  • Publication number: 20190389878
    Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder in a subject. For example, the disorder is a neurodegenerative disease.
    Type: Application
    Filed: July 1, 2019
    Publication date: December 26, 2019
    Inventors: Gregory D. CUNY, Marcie A. GLICKSMAN, Kevin J. HODGETTS, Steven L. MATHIEU, Yukari Y. PERRELLA, Vincent DARMENCY, Hrvoje LUSIC
  • Patent number: 10513521
    Abstract: The present invention provides bicyclic heteroaryl inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. Exemplary compounds include those of Formula I: These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: December 24, 2019
    Assignees: The Brigham and Women's Hospital, Inc., University of Houston System, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Arthur Lee, John C. McKew, Paresma R. Patel, Paul B. Yu, Agustin H. Mohedas, Philip E. Sanderson, Gregory D. Cuny, Wei Zheng, Xiuli Huang
  • Patent number: 10406163
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: September 10, 2019
    Assignees: Massachusetts Eye & Ear Infirmary, The Brigham & Women's Hospital, Inc.
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • Patent number: 10336768
    Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder in a subject. For example, the disorder is a neurodegenerative disease.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: July 2, 2019
    Assignees: Yuma Therapeutics, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Gregory D. Cuny, Marcie A. Glicksman, Kevin J. Hodgetts, Steven L. Mathieu, Yukari Y. Perrella, Vincent Darmency, Hrvoje Lusic
  • Patent number: 10125116
    Abstract: Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound of the invention selectively inhibits a parasitic IMPDH versus a host IMPDH. Further, the invention provides pharmaceutical compositions comprising one or more compounds of the invention. The invention also relates to methods of treating various parasitic and bacterial infections in mammals. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: November 13, 2018
    Assignees: Brandeis University, University of Georgia Research Foundation, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Lizbeth K. Hedstrom, Gregory D. Cuny, Deviprasad R. Gollapalli, Sivapriya Kirubakaran, Sushil K. Maurya, Boris Striepen, Suresh K. Gorla, Corey R. Johnson, Mandapati Kavitha, Jihan Khan
  • Patent number: 10017516
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: July 10, 2018
    Assignees: The Brigham and Women's Hospital, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services, National Institutes of Health
    Inventors: Asaf Alimardanov, Gregory D. Cuny, Gurmit S. Grewal, Arthur Lee, John C. McKew, Agustin H. Mohedas, Min Shen, Xin Xu, Paul B. Yu
  • Publication number: 20170334918
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    Type: Application
    Filed: May 18, 2017
    Publication date: November 23, 2017
    Inventors: ASAF ALIMARDANOV, GREGORY D. CUNY, GURMIT SINGH GREWAL, ARTHUR LEE, JOHN C. MCKEW, AGUSTIN H. MOHEDAS, MIN SHEN, XIN XU, PAUL B. YU
  • Publication number: 20170305883
    Abstract: The present invention provides small molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    Type: Application
    Filed: October 1, 2015
    Publication date: October 26, 2017
    Inventors: Paul B. Yu, Gregory D. Cuny, Agustin H. Mohedas, Arthur Lee
  • Patent number: 9725452
    Abstract: The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 8, 2017
    Assignees: Presidents and Fellows of Harvard College, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Tufts University, University of Houston
    Inventors: Junying Yuan, Alexei Degterev, Gregory D. Cuny
  • Publication number: 20170202810
    Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents.
    Type: Application
    Filed: November 3, 2016
    Publication date: July 20, 2017
    Applicants: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Alan D. D'Andrea, Gregory D. Cuny, Ross L. Stein, Marcie Glicksman, April Case, Jun Xian, David Wilson, Min Huang
  • Publication number: 20170197968
    Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    Type: Application
    Filed: July 14, 2015
    Publication date: July 13, 2017
    Inventors: Arthur Lee, John C. McKew, Paresma R. Patel, Paul B. Yu, Agustin H. Mohedas, Philip E. Sanderson, Gregory D. Cuny, Wei Zheng, Xiuli Huang
  • Publication number: 20170190705
    Abstract: The present invention provides small molecules inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    Type: Application
    Filed: March 25, 2015
    Publication date: July 6, 2017
    Inventors: Paul B. Yu, Gregory D. Cuny, Agustin H. Mohedas